Cargando…

P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study

POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: To assess species distribution, antifungal susceptibility pattern, and associated risk factors in cases of candidemia among admitted patients in a tertiary care hospital in New Delhi, India. METHODS: Any positive blood culture b...

Descripción completa

Detalles Bibliográficos
Autores principales: Shujanya, Prateek, Raveendran, Reena, Oberoi, Jaswinder Kaur, Wattal, Chand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509765/
http://dx.doi.org/10.1093/mmy/myac072.P020
_version_ 1784797299727138816
author Shujanya, Prateek
Raveendran, Reena
Oberoi, Jaswinder Kaur
Wattal, Chand
author_facet Shujanya, Prateek
Raveendran, Reena
Oberoi, Jaswinder Kaur
Wattal, Chand
author_sort Shujanya, Prateek
collection PubMed
description POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: To assess species distribution, antifungal susceptibility pattern, and associated risk factors in cases of candidemia among admitted patients in a tertiary care hospital in New Delhi, India. METHODS: Any positive blood culture bottle which revealed budding yeast cells on gram stain was included in the study. The samples were subcultured onto blood agar and HiCrome™ Candida Differential Agar (HiMedia Laboratories Pvt. Limited, Mumbai), after which the colonies were subjected to identification with VITEK MS (bioMerieux, France). The antifungal susceptibility of each isolate was assessed with the help of Vitek 2 AST (bioMerieux, France). Fluconazole, voriconazole, caspofungin, amphotericin B, flucytosine, and micafungin were the antifungals tested for resistance. Antifungal susceptibility by broth microdilution was performed for C. auris and for fluconazole in the case of C. glabrata. Patient demographics, as well as risk factors associated with Candida infections, were collected from case files and by interviewing patients and bystanders. RESULTS: We isolated 171 fungal isolates from 160 patients admitted in the study during a period of 1 year from February 1, 2021 to January 31, 2022. Out of the 171 fungal isolates, 162 were Candida spp. Trichosporon spp. Saccharomyces cerevisiae and Fusarium spp. contributed 6, 2, and 1 isolate respectively. Among the Candida isolates, the commonest were C. auris (n = 37) followed by C. tropicalis (n = 34), C. albicans (n = 22), and C. glabrata (n = 22) (Fig. 1). The most common isolate from patients admitted to the ICU/HDU was C. auris (31%). Whereas in wards C. tropicalis (22%) and C. parapsilosis (22%) contributed the maximum number of isolates. Candida pelliculosa (n = 8) and C. tropicalis (n = 7) were the most common isolates among neonates. Antifungal susceptibility results were interpreted as per Clinical Laboratory Standards Institute M27 A2 document. Overall sensitivity was highest for Micafungin followed by amphotericin B. Micafungin was mostly sensitive for C. auris (94.11%), whereas in case of amphotericin B it was 47.22% (Table 1). The most common risk factor observed was the presence of IV line (n = 135), antimicrobial therapy (n = 126), and diabetes (n = 46). In neonates also the most common risk factor was the presence of an IV line (n = 23) followed by outborn status (babies delivered outside in other hospitals and transferred subsequently) (n = 20). A total of 30 days hospital mortality was observed to be 54.05% in patients with C auris isolates. CONCLUSION: Candida BSI etiologies are shifting away from C. albicans and towards species that have a higher propensity for developing resistance, such as the multidrug-resistant C. auris, which is rapidly spreading throughout the world. This highlights the importance of stepping up hospital infection control practices and antimicrobial stewardship initiatives in order to counteract the rapidly increasing antifungal resistance threat.
format Online
Article
Text
id pubmed-9509765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95097652022-09-26 P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study Shujanya, Prateek Raveendran, Reena Oberoi, Jaswinder Kaur Wattal, Chand Med Mycol Oral Presentations POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: To assess species distribution, antifungal susceptibility pattern, and associated risk factors in cases of candidemia among admitted patients in a tertiary care hospital in New Delhi, India. METHODS: Any positive blood culture bottle which revealed budding yeast cells on gram stain was included in the study. The samples were subcultured onto blood agar and HiCrome™ Candida Differential Agar (HiMedia Laboratories Pvt. Limited, Mumbai), after which the colonies were subjected to identification with VITEK MS (bioMerieux, France). The antifungal susceptibility of each isolate was assessed with the help of Vitek 2 AST (bioMerieux, France). Fluconazole, voriconazole, caspofungin, amphotericin B, flucytosine, and micafungin were the antifungals tested for resistance. Antifungal susceptibility by broth microdilution was performed for C. auris and for fluconazole in the case of C. glabrata. Patient demographics, as well as risk factors associated with Candida infections, were collected from case files and by interviewing patients and bystanders. RESULTS: We isolated 171 fungal isolates from 160 patients admitted in the study during a period of 1 year from February 1, 2021 to January 31, 2022. Out of the 171 fungal isolates, 162 were Candida spp. Trichosporon spp. Saccharomyces cerevisiae and Fusarium spp. contributed 6, 2, and 1 isolate respectively. Among the Candida isolates, the commonest were C. auris (n = 37) followed by C. tropicalis (n = 34), C. albicans (n = 22), and C. glabrata (n = 22) (Fig. 1). The most common isolate from patients admitted to the ICU/HDU was C. auris (31%). Whereas in wards C. tropicalis (22%) and C. parapsilosis (22%) contributed the maximum number of isolates. Candida pelliculosa (n = 8) and C. tropicalis (n = 7) were the most common isolates among neonates. Antifungal susceptibility results were interpreted as per Clinical Laboratory Standards Institute M27 A2 document. Overall sensitivity was highest for Micafungin followed by amphotericin B. Micafungin was mostly sensitive for C. auris (94.11%), whereas in case of amphotericin B it was 47.22% (Table 1). The most common risk factor observed was the presence of IV line (n = 135), antimicrobial therapy (n = 126), and diabetes (n = 46). In neonates also the most common risk factor was the presence of an IV line (n = 23) followed by outborn status (babies delivered outside in other hospitals and transferred subsequently) (n = 20). A total of 30 days hospital mortality was observed to be 54.05% in patients with C auris isolates. CONCLUSION: Candida BSI etiologies are shifting away from C. albicans and towards species that have a higher propensity for developing resistance, such as the multidrug-resistant C. auris, which is rapidly spreading throughout the world. This highlights the importance of stepping up hospital infection control practices and antimicrobial stewardship initiatives in order to counteract the rapidly increasing antifungal resistance threat. Oxford University Press 2022-09-20 /pmc/articles/PMC9509765/ http://dx.doi.org/10.1093/mmy/myac072.P020 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Shujanya, Prateek
Raveendran, Reena
Oberoi, Jaswinder Kaur
Wattal, Chand
P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title_full P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title_fullStr P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title_full_unstemmed P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title_short P020 Risk factors, speciation ,and antifungal susceptibility in candidemia patients: An observational study
title_sort p020 risk factors, speciation ,and antifungal susceptibility in candidemia patients: an observational study
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509765/
http://dx.doi.org/10.1093/mmy/myac072.P020
work_keys_str_mv AT shujanyaprateek p020riskfactorsspeciationandantifungalsusceptibilityincandidemiapatientsanobservationalstudy
AT raveendranreena p020riskfactorsspeciationandantifungalsusceptibilityincandidemiapatientsanobservationalstudy
AT oberoijaswinderkaur p020riskfactorsspeciationandantifungalsusceptibilityincandidemiapatientsanobservationalstudy
AT wattalchand p020riskfactorsspeciationandantifungalsusceptibilityincandidemiapatientsanobservationalstudy